New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated
Go back to New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated| Amarin Corp Plc (NASDAQ: AMRN) | Delayed: 15.97 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.97 | 52 Week High | $3.65 | |||
| Open | $15.97 | 52 Week Low | $1.24 | |||
| Day High | $15.97 | P/E | N/A | |||
| Day Low | $15.97 | EPS | $0.00 | |||
| Volume | 2 | |||||
